A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors Abstract #2190

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Aim(s): The aim of this prospective study was to compare the association between changes in plasma CgA and changes in tumor burden on CT in GEP-NET patients with residual disease.
Materials and methods: We included 239 patients with a CT followed by at least one additional CT between 1 and- 24 months later. Change in tumor size was defined and categorized by RECIST1.1. An event was defined as CgA measured within 6 weeks of a CT. In addition, in a post-hoc analysis an event was defined as a CgA measured 3-6 month prior to the CT. A 25% change in CgA discriminated between increased, unchanged or decreased plasma CgA levels. Patients were included in Denmark, Norway and Sweden from December 2010 to December 2013.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result